MIRAPEX ER's oppositions filed in EPO
MIRAPEX ER Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7695734 | BOEHRINGER INGELHEIM | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
Apr, 2028
(4 years from now) | |
| US8679533 | BOEHRINGER INGELHEIM | Pramipexole once-daily dosage form |
Sep, 2029
(5 years from now) | |
Mirapex Er is owned by Boehringer Ingelheim.
Mirapex Er contains Pramipexole Dihydrochloride.
Mirapex Er has a total of 2 drug patents out of which 0 drug patents have expired.
Mirapex Er was authorised for market use on 19 February, 2010.
Mirapex Er is available in tablet, extended release;oral dosage forms.
Mirapex Er can be used as treatment of parkinson's disease.
The generics of Mirapex Er are possible to be released after 08 September, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-623) | Mar 19, 2013 |
| New Dosage Form(NDF) | Feb 19, 2013 |
Drugs and Companies using PRAMIPEXOLE DIHYDROCHLORIDE ingredient
Market Authorisation Date: 19 February, 2010
Treatment: Treatment of parkinson's disease
Dosage: TABLET, EXTENDED RELEASE;ORAL
How can I launch a generic of MIRAPEX ER before it's drug patent expiration?
More Information on Dosage
MIRAPEX ER family patents
